This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject's glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject's glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject's glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide.

Disclosed herein is a method of treating nuclear protein in testis (NUT) midline carcinoma (NMC) in a subject in need thereof, comprising administering an effective amount of a bromodomain inhibitor, wherein the effective amount can be determined according to the expression levels of CD11b, which monitors responsiveness of the NMC to the bromodomain inhibitor. Also disclosed herein is a method of determining a bromodomain inhibitor treatment regimen in a subject suffering from NMC.

The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

Methods and kits for identifying abnormal urinary system cells in a sample, by contacting the cells or the sample containing same with a combination of an extract from a Ficus plant, or one or more components thereof, an acidic dye and a basic dye.

The invention provides a system, composition, and methods of using the systems and compositions for the analysis of a sample from a subject to accurately diagnose, prognose, or classify the subject with certain grades of or susceptibility to Barrett's esophagus. In some embodiments, the system of the present invention comprises a means of detecting and/or quantifying morphological features, the expression of protein, or the expression of nucleic acids in a plurality of cells and correlating that data with a subject's medical history to predict clinical outcome, treatment plans, preventive medicine plans, or effective therapies. In some embodiments, the invention relates to a method of classifying and compiling data taken from a cell sample from a subject analyzing the data, and converting the data from the system into a score by which a pathologist may calculate the likelihood that the subject develops cancer.

Methods and compositions for identifying, diagnosing, and treating neuroblastoma are disclosed.

The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.

The present invention relates to antibodies that bind to Mcm5. The invention further relates to compositions or kits comprising the antibodies, hybridomas capable of expressing the antibodies, polynucleotides, polypeptides and vectors coding for the antibodies and methods for making the antibodies.

A system for testing a biological subject includes an imaging device and an imaging agent detectable by the imaging device, for detecting amount and location of a biomarker in the biological subject. The imaging agent includes a fluorescent microsphere and a targeting member attached to the fluorescent microsphere. A method of testing a biological subject using the system includes providing the imaging agent, applying the imaging agent to a testing location of a patient and imaging the imaging agent in the testing location by the imaging device, so as to detect the amount and locations of the imaging agent. A method of screening and diagnose a cancer that is accessible via cavity of a patient, includes performing a CD44 and total protein test, and if the result is positive, performing an imaging test.

An anti-human T-cell immunoglobulin domain and mucin domain 3 (TIM-3) antibody, can bind the peptides, comprising the amino-acid sequence RKGDVSL (SEQ ID NO: 9) and/or EKFNLKL (SEQ ID NO: 10) of human TIM-3 protein. The antibody can regulate immune cell activity. The antibody or binding fragment thereof is useful in diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface TIM-3 such as lung, liver, esophageal cancer and solid tumors.